This website is intended for UK healthcare professionals only Log in | Register

Tag Archives: sacubitril/valsartan

October 2019 Br J Cardiol 2019;26(4)

News from ESC 2019

Richard Armstrong, Amar Puttana, BJC Staff

Abstract

ESC President, Professor Barbara Casadei Heart failure highlights PARAGON-HF fails primary end point but benefits for some Heart failure was a key theme of this year’s congress, accounting for more than 1,000 presentations. In the first hotline session of the Congress, the keenly awaited results from PARAGON-HF (Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction) were presented.1 Up to 64 million people worldwide have heart failure, and that number is rising as the population ages. Evidence-based treatment has focused on about half of these patients who have heart failure with reduced ejection fraction (<

| Full text

August 2017 Br J Cardiol 2017;24:(3) Online First

BCS 2017: spotlight on heart failure

BJC Staff, Dr Richard Crawley, Dr Brian Halliday, Dr Rosita Zakeri

Abstract

Landmark trials in heart failure – 30 years from CONSENSUS With 2017 marking the 30th year since the publication of CONSENSUS,1 which first reported a reduction in mortality with enalapril versus placebo in patients with advanced heart failure (HF), the BCS held a dedicated session to review the seminal clinical trials and advances in chronic heart failure management in this period. Dr Rosita Zakeri (Royal Brompton Hospital, London) reviewed this session for us and spoke to the BJC afterwards. Rosita Zakeri The era of vasodilator therapy for heart failure began in the 1990s. Professor Karl Swedberg (University of Gothenberg, Sweden) began

| Full text

October 2016 Br J Cardiol 2016;23:151–4 doi:10.5837/bjc.2016.032

Suitability for sacubitril/valsartan at discharge from hospital: an audit

Thomas Green, Kaushiki Singh, Hugh F McIntyre 

Abstract

(more…)

| Full text

October 2016 Br J Cardiol 2016;23:148–50 doi:10.5837/bjc.2016.033

Eligibility of patients for sacubitril/valsartan in a secondary care heart failure service

Freya M Lodge, Julie Phillips, Tristan Groves, Zaheer R Yousef

Abstract

(more…)

| Full text

August 2016 Br J Cardiol 2016;23:92

Correspondence: Sacubitril/valsartan: where should it sit in the heart failure pathway?

Robert Stevenson

Abstract

Sacubitril/valsartan (Entresto™, Novartis), the first angiotensin receptor blocker (ARB) and neprilysin inhibitor (NEP) combination – known as an angiotensin-receptor-neprilysin inhibitor (ARNI) – has recently been approved by the National Institute for Health and Care Excellence (NICE) in the treatment of patients with chronic heart failure.1 The guidance, largely based on results from the landmark PARADIGM- HF study,2 recommends sacubitril/valsartan as an “option” for symptomatic patients (New York Heart Association [NYHA] class II– IV) who have an ejection fraction of 35% or less and are established on a “stable dose” of an

| Full text

June 2016 Br J Cardiol 2016;23:51

New ESC heart failure guidelines

BJCardio Staff

Abstract

The 2016 guidelines include for the first time the new drug sacubitril/valsartan (previously known as LCZ696). This is the first drug in the class of angiotensin receptor neprilysin inhibitors (ARNIs) and was shown in the PARADIGM-HF trial to be superior to the angiotensin-converting enzyme (ACE) inhibitor enalapril for reducing the risk of death and hospitalisation in patients with heart failure with reduced ejection fraction (HFREF) who met strict inclusion and exclusion criteria. Professor Piotr Ponikowski (Chairperson of the ESC Guidelines Task Force), said: “The issue of how to include LCZ696 in the treatment algorithm generated a lot

| Full text

June 2016 Br J Cardiol 2016;23:51

NICE go-ahead for sacubitril/valsartan

BJCardio Staff

Abstract

Sacubitril/valsartan is the first of a new kind of drug called angiotensin receptor neprilysin inhibitors. NICE recognised sacubitril/valsartan as an innovative treatment, which it says “offers the potential to prevent deaths and reduce the more than 30,000 hospital admissions for this condition each year in England”.  It is the first non-cancer drug to be fast-tracked through the Medicines and Healthcare Products Regulatory Agency’s Early Access to Medicines Scheme. The scheme aims to give patients with life threatening or seriously debilitating conditions access to medicines before they are licensed where there is a clear, unmet medi

| Full text

For healthcare professionals only

Add Banner

Close

You are not logged in

You need to be a member to print this page.
Find out more about our membership benefits

Register Now Already a member? Login now
Close

You are not logged in

You need to be a member to download PDF's.
Find out more about our membership benefits

Register Now Already a member? Login now